HOME >> BIOLOGY >> NEWS
Gene therapy trial using cold virus to begin at UK

LEXINGTON, KY -- For the first time at the University of Kentucky, researchers are beginning a Phase II clinical trial to evaluate a gene therapy product that may be used as a treatment for ovarian cancer. The clinical trial will evaluate the effectiveness of the p53 gene inserted into an adenovirus (common cold virus) in combination with standard surgery and chemotherapy to treat ovarian cancer that has spread to the abdominal cavity.

"Gene therapy is a novel approach to the treatment of ovarian cancer, as well as several other types of cancer," said Holly Gallion, M.D., professor, Department of Obstetrics and Gynecology, UK College of Medicine, and principal investigator at UK for the clinical trial. "We hope that gene therapy will prove to be another effective tool to fight ovarian cancer, along with surgery and chemotherapy."

Many diseases, including cancer, result from defective, or mutated, genes in cells. The goal of gene therapy is to deliver a correct copy of the mutated gene directly to the nucleus of the abnormal cells, thereby restoring normal function of the gene.

To insert the corrective gene into the nucleus, the corrective gene can be encapsulated in liposomes, small balls made of molecules that resemble cell membranes, or viruses. The adenovirus, or common cold virus, often is used as the gene-delivery vector in gene therapy.

Ovarian cancer is the most serious of all gynecological cancers. It is the fifth most common cancer among women, accounting for 4 percent of all cancers in women. According to the American Cancer Society, about 25,200 new cases of ovarian cancer will be diagnosed in the United States in 1999, and about 14,500 women will die from it.

About 76 percent of ovarian cancer patients survive one year after diagnosis, and more than 40 percent survive longer than five years. If diagnosed and treated early, before the cancer has spread beyond the ovaries, 9
'"/>

Contact: Maureen McArthur
mhmcar2@pop.uky.edu
606-323-6363
University of Kentucky Medical Center
23-Jul-1999


Page: 1 2 3

Related biology news :

1. Targeted therapy knocks out pediatric brain cancer in mice
2. New anti-inflammatory strategy for cancer therapy identified by UCSD researchers
3. Columbia research to examine gene influence on severity of peridontal disease, therapy response
4. Case for IBD combination therapy comes from research at Baylor, MIT and Hebrew University
5. The search for a kinder, gentler chemotherapy
6. Embryonic stem cell therapy shows steady benefits in rebuilding infarcted heart
7. Retroviral gene therapy? ASLV, HIV, and MLV show distinct target site preferences
8. Gene changes linked to increased eye pressure may have implications for glaucoma therapy
9. Jefferson Lab detector technology aids development of cystic fibrosis therapy
10. Stroking up cellular therapy
11. Smart gene therapy protects against damage from heart attack

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/18/2020)... , ... July 17, 2020 , ... Commercial launch readiness ... pharma’s ability to discover a COVID cure or vaccine, the global economic downturn will ... price pressure is not going away and capturing full value from every product launch ...
(Date:7/10/2020)... ... July 09, 2020 , ... Today CJ BIO announced the ... share insight on the “fifth taste” phenomenon that is revolutionizing ingredient mixes, nutritional content ... will be live on Monday, July 13, 2020 at11:00 AM (CDT) during SHIFT20, the ...
(Date:7/2/2020)... , ... July 01, 2020 , ... ... its phase 1a findings of Neihulizumab, a biologic for the treatment of steroid-refractory ... 2020. Led by hemato-oncologist Dr. Paul J Martin of the Fred Hutchinson Cancer ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... ... July 16, 2020 , ... Medial EarlySign ... detection and prevention of high-burden diseases, and Centric Consulting, a business and technology ... to utilize existing data in order to identify and prioritize patients for care. ...
(Date:7/10/2020)... ... July 09, 2020 , ... In ... commonly used to suppress pigment formation in zebrafish embryos, maintaining optical transparency to ... by Dr MA has been using the zebrafish model to investigate the causes ...
(Date:7/1/2020)... ... June 29, 2020 , ... MedShift , a leading ... despite many obstacles created as a result of COVID-19. As a provider at ... medical practices and medical manufacturers by expanding access to device offerings, technology services, ...
(Date:6/28/2020)... ... June 25, 2020 , ... ... develop a vaccine or drug treatment. In an effort to better understand the ... released the world’s largest imaging dataset portraying therapeutic compound effects from over 1,600 ...
Breaking Biology Technology:
Cached News: